CA2000650A1 - Produit et procede pour le traitement et la prevention des thrombi intravasculaires et de l'atherosclerose - Google Patents

Produit et procede pour le traitement et la prevention des thrombi intravasculaires et de l'atherosclerose

Info

Publication number: CA2000650A1
Authority: CA; Canada
Prior art keywords: heparin; treatment; atherosclerosis; prevention; vascular
Prior art date: 1989-10-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2000650

Other languages

English (en)

Inventor

Louis Jaques

Thomas Usher

Linda Hiebert

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-10-13

Filing date

1989-10-13

Publication date

1991-04-13

1989-10-13 Application filed by Individual filed Critical Individual

1989-10-13 Priority to CA 2000650 priority Critical patent/CA2000650A1/fr

1991-04-13 Publication of CA2000650A1 publication Critical patent/CA2000650A1/fr

Status Abandoned legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 14
201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 10
230000002265 prevention Effects 0.000 title claims abstract description 7
238000000034 method Methods 0.000 title claims description 9
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 32
229920000669 heparin Polymers 0.000 claims abstract description 32
229960002897 heparin Drugs 0.000 claims abstract description 32
210000003462 vein Anatomy 0.000 claims description 10
208000007536 Thrombosis Diseases 0.000 claims description 9
230000002792 vascular Effects 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 6
230000003412 degenerative effect Effects 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 3
241001465754 Metazoa Species 0.000 claims description 3
210000001367 artery Anatomy 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 2
230000007850 degeneration Effects 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
238000011287 therapeutic dose Methods 0.000 claims 3
229940124597 therapeutic agent Drugs 0.000 claims 2
239000004480 active ingredient Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
241000700159 Rattus Species 0.000 description 14
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
210000002381 plasma Anatomy 0.000 description 5
230000003143 atherosclerotic effect Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
210000003038 endothelium Anatomy 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
238000010171 animal model Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000005755 formation reaction Methods 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
230000003902 lesion Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
230000001732 thrombotic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
241000283690 Bos taurus Species 0.000 description 1
208000004434 Calcinosis Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010011091 Coronary artery thrombosis Diseases 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
208000037516 chromosome inversion disease Diseases 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
208000002528 coronary thrombosis Diseases 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000000523 sample Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229950003937 tolonium Drugs 0.000 description 1
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA 2000650 1989-10-13 1989-10-13 Produit et procede pour le traitement et la prevention des thrombi intravasculaires et de l'atherosclerose Abandoned CA2000650A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2000650 CA2000650A1 (fr)	1989-10-13	1989-10-13	Produit et procede pour le traitement et la prevention des thrombi intravasculaires et de l'atherosclerose

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2000650 CA2000650A1 (fr)	1989-10-13	1989-10-13	Produit et procede pour le traitement et la prevention des thrombi intravasculaires et de l'atherosclerose

Publications (1)

Publication Number	Publication Date
CA2000650A1 true CA2000650A1 (fr)	1991-04-13

Family

ID=4143324

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2000650 Abandoned CA2000650A1 (fr)	1989-10-13	1989-10-13	Produit et procede pour le traitement et la prevention des thrombi intravasculaires et de l'atherosclerose

Country Status (1)

Country	Link
CA (1)	CA2000650A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5922690A (en) *	1996-04-25	1999-07-13	Van Gorp; Cornelius L.	Dermatan disulfate, an inhibitor of thrombin generation and activation
US6409987B1 (en)	1999-04-07	2002-06-25	Intimax Corporation	Targeted agents useful for diagnostic and therapeutic applications
US6518244B2 (en)	2000-03-09	2003-02-11	Intimax Corporation	Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof

1989
- 1989-10-13 CA CA 2000650 patent/CA2000650A1/fr not_active Abandoned

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5922690A (en) *	1996-04-25	1999-07-13	Van Gorp; Cornelius L.	Dermatan disulfate, an inhibitor of thrombin generation and activation
US6409987B1 (en)	1999-04-07	2002-06-25	Intimax Corporation	Targeted agents useful for diagnostic and therapeutic applications
US6518244B2 (en)	2000-03-09	2003-02-11	Intimax Corporation	Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof

Similar Documents

Publication	Publication Date	Title
EP0343241B1 (fr)	1994-02-16	Procede inhibant la thrombose arterielle due aux plaquettes
DE69212608T2 (de)	1996-11-28	Arzneimittel enthaltend oral absorbierbare Glycosaminoglycane
JP3388117B2 (ja)	2003-03-17	カイガンショウ抽出物に基づく血小板反応性調節剤の調製方法
KR950009094B1 (ko)	1995-08-14	과유지질혈증 및 아테롬성 동맥경화증의 방지 및 치료용 피리독신 유도체를 함유한 제약학적 조성물
RU2262933C2 (ru)	2005-10-27	Медицинские композиции, содержащие аспирин
HK14494A (en)	1994-03-04	Medicaments containing dipyridamol or mopidamol and o-acetylsalicylic acid, or its physiologically compatible salts, process for their manufacture and their use in combating the formation of thrombus
JP2004534087A (ja)	2004-11-11	炎症性腸疾患の治療のためのスロデキシドの使用
US4302577A (en)	1981-11-24	Process for preparing CSA or CSC
Dressman et al.	1992	Absorption of flurbiprofen in the fed and fasted states
ES2298342T3 (es)	2008-05-16	Glicina betaina y su uso como agente anti-hemorragico.
KR20140097132A (ko)	2014-08-06	허혈성 손상을 치료하기 위한 시스테아민 및/또는 시스타민
CA1326453C (fr)	1994-01-25	Composition pharmaceutique a base de pentamidine
JPH05504785A (ja)	1993-07-22	新規なへパリン誘導体
JP2000026300A (ja)	2000-01-25	血管内皮細胞保護医薬組成物
CA2000650A1 (fr)	1991-04-13	Produit et procede pour le traitement et la prevention des thrombi intravasculaires et de l'atherosclerose
EP0532706B1 (fr)	1995-05-10	REDUCTION D'OCCLUSIONS DE VAISSEAUX CARDIOVASCULAIRES A L'AIDE D'ASCORBATE ET D'INHIBITEURS DE LIAISON DE LA LIPOPROTEINE (a)
CA1300504C (fr)	1992-05-12	Preparation pharmaceutique pour le traitement de la cataracte
Wood et al.	1973	Trial of aspirin and RA 233 in prevention of post-operative deep vein thrombosis
JP2002503270A (ja)	2002-01-29	体外血液回路における血餅形成を防止するためのオリゴ糖の使用
TW577741B (en)	2004-03-01	Novel pharmaceutical combination for treating pain comprising paracetamol and buspirone
HU206261B (en)	1992-10-28	Process for producing pharmaceutical compositions suitable for treating pulmonary hypertension caused by neutralization by heparin protemin, and comprising 7-oxabicyclo/2.2.1/-5-heptanoic acid derivative as active ingredient
CA2195863C (fr)	2001-04-17	Remede contre l'endotoxinemie et des defaillances d'organes multiples induites par celle-ci
WO2000018418A3 (fr)	2000-07-20	Inhibition de la falciformation des erythrocytes par n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester
JPH0148249B2 (fr)	1989-10-18
JP3811500B2 (ja)	2006-08-23	動脈硬化の除去のためのヒアルロン酸を含む薬剤組成物

Legal Events

Date	Code	Title	Description
1996-10-09	EEER	Examination request
2000-06-23	FZDE	Dead